Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioLine Rx Ltd receives orphan drug designation for novel stem cell mobilization treatment


Thursday, 23 Jan 2014 07:00am EST 

BioLine Rx Ltd:Says it has received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia (AML).Says orphan drug designation is granted to therapeutics intended to treat rare diseases that affect not more than 200,000 people in the United States.Says orphan drug designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.Says the Orphan Drug Designation was granted for use of BL-8040, in combination with granulocyte colony-stimulating factor (G-CSF), to mobilize human stem cells from the bone marrow to the peripheral blood for collection for autologous or allogeneic (donor-based) transplantation. 

Company Quote

50.1
-1.2 -2.34%
23 Oct 2014